New pill is effective against gonorrhea as antibiotic resistance surges, study shows
A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial, according to a study published Monday in The Lancet. If approved, it would become the first new class of antibiotic for the sexually transmitted infection in more than two decades.
The pill, called gepotidacin, was approved by the Food and Drug Administration in March to treat uncomplicated urinary tract infections in women and girls 12 and up — the most common type of infection in women. The drug is sold under the name Blujepa.
A new treatment option is important, experts say, because bacteria that commonly cause STDs are increasingly becoming resistant to the standard antibiotics, making treatment more difficult.
There are an estimated 82 million new cases of gonorrhea globally each year, according to GSK. In the United States, rates of reported gonorrhea have increased 118% from 2009 to 2021, with more than 640,000 cases being reported to the Centers for Disease Control and Prevention in 2022.
Gonorrhea has developed resistance to nearly all the antibiotics used for its treatment, according to the CDC.
If left untreated, gonorrhea can lead to serious health complications, including swollen and painful joints, liver inflammation and heart and brain damage. It can also increase the risk of infertility in women.
Gepotidacin is part of a new class of antibiotics called triazaacenaphthylenes, which work by targeting two key enzymes that gonorrhea needs to copy itself and survive.
In a phase 3 clinical trial of more than 600 adults and teens, gepotidacin was shown to successfully treat about 92% of patients when taken twice daily, compared to about 91% in a group of patients who got a standard treatment.
The most common side effect was gastrointestinal issues, with almost all reported being 'mild or moderate.'
Crucially, the study authors wrote, the pill was effective against strains of gonorrhea bacteria that are resistant to existing antibiotics.
Dr. Sovrin Shah, an associate professor of urology at Mount Sinai Hospital in New York who was not involved in the study, called the GSK pill 'a welcome addition.'
'Antibiotic-resistant gonorrhea is a public health concern,' Shah said. 'The rate of STIs is significant in the U.S.'
A spokesperson for GSK said the company plans to file approval with the FDA 'in the coming months' with a regulatory decision expected in the second half of the year.
The company said it's seeking approval for gepotidacin as an alternative to first-line therapy when such treatment is inappropriate — such as when the patient is intolerant to the existing treatment or unwilling to use it.
The company is also investigating whether gepotidacin works in other sexually transmitted diseases.
In an editorial that accompanied the study, Magnus Unemo, director of the World Health Organization's division that oversees gonorrhea, said GSK's pill is 'promising,' but added that challenges to keep gonorrhea as a treatable infection will continue.
Unemo also stressed improved prevention, including the promotion of safe sex and condom use, early diagnosis and surveillance.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
2 days ago
- NBC News
As ivermectin goes over the counter, some pharmacists worry about a lack of guidance
Boise, Idaho, pharmacist Matt Murray has no choice but to disappoint the handful of people who call him every day asking for a drug used to treat parasitic worms. He could give them the medication, called ivermectin, but only with a doctor's note. The callers aren't in the throes of an active intestinal worm infestation, Murray said. They simply want access to the pills without having to see a doctor first. 'A lot of people are calling, asking, 'Do you guys have it for sale? Can I buy it? How do I get it?'' said Murray, the director of operations for the independent Customedica Pharmacy. 'Not so much, 'How does it work? What is it for?'' The volume of such calls has increased sharply since mid-April, when Idaho Gov. Brad Little, a Republican, signed a bill into law mandating that ivermectin be available to anyone who wants it over the counter. While the law technically says that pharmacists like Murray can sell the drug over the counter, the Food and Drug Administration hasn't approved it to be used this way. 'I don't feel that we could just sell prescription ivermectin,' Murray said. 'It's not designed or packaged for retail sale.' That hasn't stopped frenzied social media claims about ivermectin's supposed 'miraculous' abilities to cure everything from Covid to cancer. 'Ivermectin eliminated the cancer on the skin of my shoulder and it only took 3 weeks,' one person wrote on X. 'It's also working wonders on my eczema,' another wrote on the platform. Ivermectin has never been formulated or labeled specifically for over-the-counter use, like aspirin or an antacid. Without proper guidance, there is concern that people could overdose on the medication. Interest in using drugs or experimental treatments in unapproved ways has gained steam with Robert F. Kennedy Jr.'s appointment as head of the Department of Health and Human Services. Kennedy recently said on a podcast that people should have access to controversial alternative therapies like stem cells and chelation therapy to remove heavy metals from the body. The FDA has warned that neither should be used without oversight from a doctor. The hype has prompted lawmakers in 16 states, including Idaho, to propose and in some cases pass legislation to make the pills readily available for anyone without a prescription. While health insurance covers many prescription drugs, including ivermectin, it doesn't cover over-the-counter medicines. This year, two other GOP-led states — Arkansas and Tennessee — passed over-the-counter ivermectin laws. NBC News called 15 independent pharmacies in those states, plus Idaho, to ask whether pharmacists could provide ivermectin without a prescription. Not a single one said they'd sell the drug over the counter, despite the new laws. All, however, appeared to be sympathetic to the request. One pharmacist in Arkansas took the time to explain that he needed to wait until the FDA provided guidance on over-the-counter ivermectin. Until then, he and all the others said, over-the-counter access to ivermectin would have to wait. Pharmacists say that just because over-the-counter ivermectin is written into law doesn't mean it should be made available to anyone who asks for it. They still rely on federal health guidance. 'Most over-the-counter drugs, especially ones that were prescriptions at one point, go through some FDA approval process,' Murray said. 'In that process, it gets decided what the labeling is going to say,' including warnings and directions. Republican lawmakers in Alabama, Georgia, Kentucky, Louisiana, Maine, Minnesota, Mississippi, New Hampshire, North Carolina, North Dakota, Pennsylvania, South Carolina and West Virginia have also proposed bills to make ivermectin available over the counter. Nearly all would simply permit health care providers and pharmacists to distribute ivermectin without a prescription. Most, like the one proposed in Alabama, would also protect pharmacists from any possible disciplinary action such as fines or license suspension from pharmacy licensing boards for dispensing it. Maine's proposed legislation specifically permits ivermectin to be sold to people who want to try it for Covid, cancer or the flu. Mississippi's bill would limit over-the-counter ivermectin to anyone 18 and older. The drug likely wouldn't be placed on store shelves, but be kept behind pharmacy counters, much like some cold medicines. Even if states do pass laws protecting pharmacists from disciplinary action, like the proposed legislation in Alabama, Murray said that he and his colleagues remain concerned. 'If you dispense something that doesn't have directions or safety precautions on it, who's ultimately liable if that causes harm?' Murray said. 'I don't know that I would want to assume that risk.' The Food and Drug Administration warns that taking large doses of ivermectin 'can be dangerous' and cause vomiting, diarrhea, low blood pressure, seizures, coma and even death. The drug could also interact with other medications like blood thinners, the FDA says. A spokeswoman for CVS Health said that while its pharmacies are able to dispense ivermectin with a prescription, they are 'not currently selling ivermectin over the counter' in any state. Walgreens declined to comment. What ivermectin is — and isn't Ivermectin was discovered by Japanese biochemist Satoshi Ōmura in the 1970s, first as a veterinary drug and then as a groundbreaking treatment for dangerous and disfiguring tropical diseases such as river blindness, as well as tapeworms, scabies and other worm-related infections. Hundreds of millions of people in mostly underdeveloped countries have used it safely with minimal side effects, such as fatigue or diarrhea, for decades. During the pandemic, the true benefit of the drug got twisted and distorted amid a social media frenzy. When mainstream doctors and scientists insisted that ivermectin didn't treat Covid, mostly conservative groups embraced it in direct opposition to public health officials. Podcaster Joe Rogan told his tens of millions of followers that ivermectin worked to cure him of Covid in 2021, prompting many people to seek out the drug as a way to treat mild or moderate cases of the virus. While there was early hope that ivermectin could ease Covid symptoms, it didn't treat respiratory viruses. It still doesn't. Ivermectin has also been touted as a cancer cure. On the same podcast, actor Mel Gibson claimed ivermectin had wiped out Stage 4 cancer in three of his friends. Gibson offered no proof. Some cancer patients believed the promises, with potentially devastating results. 'I tried that last year,' Scott Adams, the creator of the 'Dilbert' comic strip, wrote on X, 'to no effect.' Adams, a vocal Donald Trump supporter, revealed in May that he'd been diagnosed with advanced prostate cancer. 'There are claims of it working, but I am aware of no patient who benefitted from it.' Adams asked his social media followers to stop inundating him with advice to take ivermectin. Adams wrote that his 'odds of survival have probably jumped from zero to 30%' because he decided on a different treatment and will be 'working with top doctors in the field.' When one person pleaded with him in the comments not to discourage people from trying ivermectin, the cartoonist didn't play around: 'Your advice could kill people if they delay other treatments.' There's simply no evidence that ivermectin treats cancer, said Dr. Harold Burstein, a breast oncologist at Dana-Farber Cancer Institute in Boston. He knows because he's looked for it, without success. Since the Rogan podcast featuring Gibson aired, Burstein has had an uptick in patients asking him about ivermectin. He scoured the medical literature looking for any shred of indication that the drug could be useful to his patients. 'There are exactly zero published clinical trials in a human being on whether ivermectin does or doesn't treat cancer,' Burstein said. 'I can assure you that if any oncologist in America had seen' a benefit to ivermectin, he said, 'they would have been eager to write it up.' Some scientists are indeed trying to figure out whether ivermectin has any impact on cancer outcomes. Researchers at Cedars-Sinai Medical Center in Los Angeles have begun a preliminary study combining ivermectin with an immunotherapy drug for patients with metastatic triple-negative breast cancer. Final results aren't expected anytime soon. Doctors tried to make ivermectin 'work' Ivermectin is manufactured in the U.S. by Merck. The company said in a statement that ivermectin should only be used within the approved FDA framework. 'The use of ivermectin is not supported beyond the doses and populations indicated in the regulatory agency-approved prescribing information,' a Merck spokesperson wrote in an email. Despite the growing push for over-the-counter ivermectin, there's no sales data available for how many people are buying the pills. Focusing on making ivermectin available without a doctor's prescription is the latest in a trend of mostly conservative politicians sidestepping expert medical advice. Utah and Florida, for example, recently banned community water fluoridation, despite decades of widespread evidence that it drastically reduces tooth decay. Dr. Hugh Cassiere, director of critical care services for South Shore University Hospital, part of Northwell Health in New York, said, 'This is about constituents who either heard, read or saw something on social media and now have an idea that this is something good. They're going right to their congressman or senator to demand access.' 'That's not how medicine should work,' he said. Scientists did, in fact, study whether ivermectin helped people with Covid. Dr. Adrian Hernandez, a cardiologist with the Duke Clinical Research Institute in Durham, North Carolina, led a large research project that ultimately showed ivermectin had no benefit in treating acute Covid. 'It's always great that legislators care about the health of the state,' Hernandez said. 'But ivermectin didn't help patients get better any faster.' Hernandez's study was posted on a preprint server called medRxiv in 2022. Studies posted on the site are considered preliminary because they haven't been peer-reviewed. A second 2022 paper published by the New England Journal of Medicine found that Covid patients treated with ivermectin weren't any less likely to be hospitalized than people who didn't get the drug. A third study that did suggest a benefit was later retracted because it contained fraudulent data, according to the publisher. None of this stopped many from demanding access to the drug. During the pandemic, hospitals reported a spike in patients who had been poisoned after taking veterinary-grade ivermectin intended for livestock. Two deaths in New Mexico were linked to the drug. Even the FDA warned that high doses of ivermectin can cause seizures, coma and death. 'You are not a horse. You are not a cow. Seriously, y'all. Stop it,' the FDA tweeted on Aug. 21, 2021. The controversial post was later deleted but can still be accessed through web archives. A Merck spokesperson said the drug shouldn't be used for anything other than clearing parasitic infestations. Northwell Health's Cassiere said medications, especially ivermectin, should only be used after talking with a qualified health care provider, no matter how politicians vote. 'If you're not an expert, if you did not go to medical school, nurse practitioner school, physician assistant school, and don't have the proper training, then you should not be recommending therapies outside of that expertise,' he said. 'Are you going to get a bank loan at the deli on the corner? I don't think so.'
Daily Mail
5 days ago
- Daily Mail
Subtle warning signs of 'silent disease' 16m Americans are living with and don't know
Nearly 16 million people have the most deadly type of liver disease, yet 80 percent of them have no idea. About five percent of adults worldwide have metabolic dysfunction-associated steatohepatitis (MASH) a serious liver condition caused by fat buildup, inflammation, and scarring. It's the most dangerous type of fatty liver disease MASH triggers liver scarring, which can progress to cirrhosis, and significantly increases the risk of heart disease, chronic kidney disease, and liver cancer. Just one in five Americans with the condition are actually diagnosed. Most patients do not experience symptoms until the damage is irreversible, making it a 'silent disease'. However, as the condition progresses, individuals may experience fatigue, pain or discomfort in the upper right belly, unexplained weight loss, weakness, and in some cases, jaundice (yellowing of the skin and eyes). A coalition of researchers from the US, Europe, and South Africa said that MASH-related liver failure and other complications, including deaths, are becoming more severe and common. The scientists behind the report, published in The Lancet Regional Health Europe, are calling for a doubling in MASH diagnosis rates from the 2022 level, about 13 percent (the current rate is just under 20 percent). They estimated that about 2.6 million people in the US, UK, Germany, and France have been diagnosed with MASH. But if testing were adequately improved and scaled up to become more accessible and commonplace, that figure could balloon to 6.1 million. People with type 2 diabetes, obesity, and heart disease should be prioritized for blood work and other screening tests, which will need to skyrocket from about two million to 36 million. Follow-up testing also needs to jump by nearly 1,300 percent to meet patient needs, and in more settings than liver clinics, such as family doctors' offices, and with diabetes and heart doctors. People with diabetes are especially prone to liver damage leading to MASH. Around 30 to 60 percent of diabetics also have MASH. Obesity is another leading risk factor, with estimates suggesting that 75 percent of overweight people and 90 percent with obesity will develop the condition. People with MASH also have a tripled risk of also developing heart disease, including coronary artery disease, stroke, and heart failure, compared to people without the condition. MASH diagnosis is poised for a major shift, mirroring past breakthroughs in chronic disease management. With new treatments approved and others on the horizon, the focus now turns to fixing systemic roadblocks. Currently, limited access to non-invasive tests and reliance on specialists leave most cases undetected until late stages. MASH arises from a cascade of liver damage typically linked to a buildup of fat in the liver, which triggers inflammation that damages liver cells and activates scar-forming cells. What was once healthy liver tissue becomes stiff, progressively crippling the liver's ability to detoxify blood. Though this is often painless until the damage becomes too severe to be reversed. If caught early, people can live normal lifespans with MASH. Lifestyle changes - eating a healthier diet, exercising regularly, and losing between five and 10 percent of one's body weight - can slow down the progression of MASH and repair some of the damage. Doctors may prescribe resmetirom, the first FDA-approved medication for MASH, to work hand-in-hand with those lifestyle changes. But severe damage can cause deadly conditions that cut a person's life drastically short. 'Each late-stage MASH diagnosis represents a missed opportunity for earlier intervention to prevent disease progression, threatening worse [liver] and [non-liver] outcomes for people living with the condition and greater costs for individuals, health systems, and societies,' researchers told a Barcelona medical conference this week. The solution requires concrete changes from moving diagnostics to implementing automated tools in electronic records. The researchers said that success in improving diagnostics goes beyond devising better tests. A fundamental reworking of methods of care is needed that catches at-risk patients before irreversible damage occurs. 'Paradigm shifts do not occur in a vacuum, but arise when leaps in science, technology, and innovation are coupled with changes in perception and understanding within a community,' they said. 'A confluence of factors in 2024 and expected drug approvals in many European countries in 2025 point to a near term tipping point for MASH diagnoses; nonetheless, focused and sustained efforts are needed to turn such opportunities into reality.'
NBC News
6 days ago
- NBC News
Four states petition the FDA to lift abortion pill restrictions
Four states petitioned the Food and Drug Administration on Thursday to lift its lingering restrictions on abortion pills. The attorneys general of California, Massachusetts, New Jersey and New York argue in the petition that the FDA's current regulations make it difficult to prescribe mifepristone — one of two pills involved in a medication abortion — in primary care settings, despite evidence that it's safe to do so. 'Given mifepristone's 25-year safety record, there is simply no scientific or medical reason to subject it to such extraordinary restrictions,' New York Attorney General Letitia James said in a statement. 'The FDA must follow the science and lift these unnecessary barriers that put patients at risk and push providers out of care.' The drug is a central flash point in the abortion debate. Many anti-abortion groups see restricting who can get mifepristone or rescinding its approval as one of the most effective ways to limit abortion access nationwide. The petition comes just days after FDA Commissioner Marty Makary said he was committed to conducting a safety review of mifepristone. Health and Human Services Secretary Robert F. Kennedy Jr. and Sen. Josh Hawley, R-Mo., each requested the review following the release of a paper, which was neither peer-reviewed nor published in a medical journal, that claimed to find a high rate of serious adverse events in women who recently took the medication. Researchers who study reproductive health said the report amounts to junk science and exaggerates the risks of mifepristone. They note that it does not meet basic research standards, relying on overly broad definitions and failing to disclose which database it used. The report was released by the Ethics and Public Policy Center, a conservative think tank that served on the advisory board of Project 2025, a right-wing policy initiative that called for the FDA to walk back its approval of mifepristone. The attorneys general said Thursday that the FDA should use the safety review as an opportunity to remove barriers to accessing mifepristone nationwide — or, at minimum, in the four states involved in the petition. The FDA regulates certain medications with serious safety concerns via a drug safety program called Risk Evaluation and Mitigation Strategies (REMS). Mifepristone is currently part of that program, though a wealth of research has shown that less than 0.5% of women who take it have serious adverse reactions. Studies have also demonstrated that prescribing mifepristone through telehealth is as safe and effective as administering it in person. As part of the REMS program, mifepristone is subject to a few restrictions: People who prescribe the pills must be certified health care providers, and pharmacies must obtain certifications to dispense the medication. Patients who receive mifepristone must also sign a form attesting that they intend to end their pregnancy. The attorneys general said in their petition that those restrictions are burdensome and unnecessary. They claim that many primary care and family medicine physicians aren't able or willing to take on the administrative burden of getting certified to prescribe the pills, or are worried about being added to a list of national or local abortion providers. The FDA has already lifted several restrictions on mifepristone over the last decade. In 2016, it extended the window in which mifepristone could be used to terminate pregnancies from seven weeks' gestation to 10 weeks. In 2019, it approved a generic form of the medication, which increased supply. And in 2021, it eliminated a requirement to dispense mifepristone in person, allowing the drug to be prescribed via telehealth and sent by mail. Anti-abortion groups have called on the FDA to reinstate those restrictions, often pointing to misleading studies that suggest the medication has harmful effects. The April report that launched the FDA safety review, for instance, claims to find a 22-times higher rate of serious complications from mifepristone than reported by the agency. In their petition Thursday, the four attorneys general denounced recent attempts to challenge mifepristone's safety, which they said rely on methodologically flawed research. A coalition of anti-abortion groups sued the FDA in 2022 over its approval of mifepristone, citing two studies from the Charlotte Lozier Institute, a group that opposes abortion, that claimed to show severe complications from the drug. The lawsuit was ultimately thrown out by the Supreme Court and the studies were later retracted by a medical publisher. The Charlotte Lozier Institute released another paper last month claiming that a growing number of emergency room visits after abortions are incorrectly attributed to miscarriages, thereby masking abortion complications. Rachel Jones, a principal research scientist at the Guttmacher Institute, a research organization that supports abortion access, said the data only captures a small portion of abortions and is skewed in favor of those that are potentially higher risk. Some of the same data was used in the retracted studies, she said. Jones added that the timing of the new reports from anti-abortion groups is not coincidental. 'The anti-choice people are really going after medication abortion and doing whatever they can to get the FDA under the Trump administration to revisit the availability of the drug,' she said.
